Rural treatment of COVID-19 patients with pirfenidone, nitazoxanide and colchicine. Case series

dc.creatorITURBE ESQUIVEL, BRANDON;#0000-0003-1518-8176
dc.creatorMeneses Calderón, José;#0000-0001-6848-8434
dc.creatorConcepción Carrillo, Luis Edgar;x1357352
dc.creatorMendieta Zerón, Hugo; 45175
dc.creatorITURBE ESQUIVEL, BRANDON
dc.creatorMeneses Calderón, José
dc.creatorConcepción Carrillo, Luis Edgar
dc.creatorMendieta Zerón, Hugo
dc.date2022-07-05T02:58:58Z
dc.date2022-07-05T02:58:58Z
dc.date2022-05-30
dc.date.accessioned2022-10-13T00:29:23Z
dc.date.available2022-10-13T00:29:23Z
dc.identifier1122-0643
dc.identifierhttp://hdl.handle.net/20.500.11799/113193
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4156236
dc.descriptionCombined treatments against SARS-CoV-2 are emerging and some have taken into account the post-COVID-19 fibrosis. The aim of this survey was to report the experience of treating COVID-19 patients with pirfenidone, nitazoxanide (NTZ) and colchicine. It was a case series report of COVID-19 patients treated from December 2020 to March 2021, in a rural health center located in the State of Mexico, Mexico. 23 patients were included (mean age 44.5 ± 17.1 years), 12 women (mean age 45.9 ± 17.9 years) and 11 men (mean age 43 ± 16.9 years) with four deaths (17.39%). The evolution time was of 17.3 ± 6.7 days being the main symptoms fever (82.6%), myalgia (69.6%) and cough (65.2%). The main comorbidities were overweight/obesity 18 (78.26%), type 2 diabetes mellitus (T2DM) 4 (17.39%), Chronic obstructive pulmonary disease (COPD) 5 (21.73%) and systemic hypertension 2 (8.69%). Two patients were intubated and both died; in these cases, they refused to take NTZ until after three days the medical doctor had prescribed it for the first time. It can be concluded that implementing a mixed treatment with pirfenidone, NTZ and colchicine could improve the survival rate in ambulatory patients of low socioeconomic status.
dc.languageeng
dc.publisherPAGEPress srl, Italy
dc.rightsopenAccess
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0
dc.subjectCOVID-19
dc.subjectPirfenidone
dc.subjectNitazoxanide
dc.subjectColchicine
dc.subjectMEDICINA Y CIENCIAS DE LA SALUD
dc.subjectMEDICINA Y CIENCIAS DE LA SALUD
dc.titleRural treatment of COVID-19 patients with pirfenidone, nitazoxanide and colchicine. Case series
dc.typeArtículo
dc.typearticle


Este ítem pertenece a la siguiente institución